Summary

Other Scenarios:

Buyer: Gilead Sciences, Inc. (GILD) Last Price: 50.01 Market Cap.: 45.53B
Target: Alpharma Inc. (ALO) Last Price: 36.99 Market Cap.: 1.99B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 843
Biopharmaceuticals 365
Veterinary Products and Services   7

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 22)
  • Darusentan
  • Letairis (Ambrisentan)
  • Flolan (Epoprostenol Sodium)
  • Viread (Tenofovir Disoproxil Fumarate)
Target (Total: 10)
  • Tirosint Capsule (Levothyroxine Sodium)
  • Ketoprofen Transfersome Gel
  • Kadian (Morphine Sulphate Extended Release)
  • Embeda (Abuse Resistant Morphine Sulphate/Naltrexone)
Buyer

n/a
Target
  • Alpharma Animal Health Division

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 9)
  • DATATRAK International, Inc. (DATA)
  • Novartis AG (ADR) (NVS)
  • Abbott Laboratories (ABT)
  • Genelabs Technologies (GNLB)
Target (Total: 9)
  • Bayer AG (ADR) (BAYRY)
  • Archer Daniels Midland Company (ADM)
  • Koninklijke DSM N.V. (ADR) (RDSMY)
  • Cambrex Corporation (CBM)
Buyer (Total: 9)
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
  • Roche Holding Ltd. (ADR) (RHHBY)
Target (Total: 4)
  • Teva Pharmaceutical Industries Ltd (ADR) (TEVA)
  • Alcon, Inc. (ACL)
  • Enzon Pharmaceuticals, Inc. (ENZN)
  • Accentia Biopharmaceuticals, Inc (ABPIQ)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 2,979 2,000
Revenue Per Employee 1,845,685.0 352,361.4
Total Revenue 1,371.3 175.7
Total Expenses 677.4 166.0
Other Revenue 0.0 0.0
Cost of Revenue 300.2 63.1
SG&A Expense 189.2 89.3
Research & Development 188.1 13.5
Other Operating Expense 0.0 0.0
Operating Income 693.8 9.7
Unusual Income 0.0 0.0
LT Debt to Capital 23.78 27.66
Fwd P/E 24.61 106.50
Fwd P/Rev 8.63 2.81
Book Value 4,165.9 784.6
Curr Portion of LTD/Cap Lease 6.1 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Target

Focused (): Healthcare > Biopharmaceuticals > Pain Management

Business Description

Buyer

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, the United Kingdom and the United States. Its commercial teams promote Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis and Flolan through direct field contact with physicians, hospitals, clinics and other healthcare providers. Its corporate partner, Astellas Pharma, Inc. (Astellas), promotes, sells and distributes AmBisome in the United States.In September 2007, it acquired Nycomed Limited, a wholly owned Irish subsidiary of Germany-based pharmaceutical company, Nycomed GmbH.

Target

Alpharma Inc. is a global specialty pharmaceutical company that develops, manufactures and markets pharmaceutical products for humans and animals. As of April 2, 2008, the Company operated in two business segments: Pharmaceuticals and Animal Health (AH). The Company markets an extended release morphine sulfate pain medication sold under the trademark KADIAN, in the United States and a topical non-steroidal, anti-inflammatory (NSAID) patch product sold in the United States, under the trademark FLECTOR. The Company manufactures and markets animal health products, consisting primarily of medicated feed additives (MFAs) and water soluble therapeutics for production animals, principally poultry, cattle and swine. In April 2008, ALPHARMA, Inc. announced the divestiture of its Active Pharmaceutical Ingredients (API) business to 3i.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 79.58 63.54
Operating Margin % 49.62 -14.42
Quick Ratio 2.36 3.65
Current Ratio 3.44 4.49
Coverage Ratio 0.03 -0.07
Total Assets 6,974.1 1,353.7
Return on Equity % 44.28 -11.9
Return on Assets % 26.45 -6.9
Cash+ ST Inv. Per Share 2 13.54
Total Debt 1,305.9 305.1
Total Debt to Equity % 31.35 38.89
Total Debt to Tangible Equity % 31.35 67.82
Debt to Asset % 18.73 22.54

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Target Products:

  • Alpharma Animal Health Division
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System  
Vascular Disorders  
Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Darusentan
  
Primary Pulmonary Hypertension  
Endothelin Receptor Antagonists
Therapeutics that treat hypertension by blocking the action of endothelin, which prevents/reduces constriction of the blood vessels.

Buyer Products:

  • Letairis (Ambrisentan)
  
Prostacyclins
Therapeutics that relieve pulmonary hypertension by causing vasodilation of the pulmonary blood vessels.

Buyer Products:

  • Flolan (Epoprostenol Sodium)
  
Digestive System  
Liver Disorders  
Hepatitis  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat hepatitis by inhibiting the action of reverse transcriptase, an enzyme necessary for DNA synthesis using an RNA template.

Buyer Products:

  • Viread (Tenofovir Disoproxil Fumarate)
  • Hepsera (Adefovir Dipivoxil)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • LB84451 (Pan-Caspase Inhibitor)
  • Emtriva (Emtricitabine)
  • GS 9190 (HCV Polymerase Inhibitor)
  • Viread (Tenofovir Disoproxil Fumarate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • NS4A Antagonists
  • HCV Protease And Polymerase Inhibitors
  
Endocrinology/Metabolism  
Pituitary Gland Disorders  
Pituitary Hyperthyroidism (TSH-Induced)  
Thyroid Hormones
Hormones that affect the rate of cell metabolism and blood calcium levels.

Target Products:

  • Tirosint Capsule (Levothyroxine Sodium)
  
Thyroid Gland Disorders  
Hypothyroidism  
Thyroid Hormones
Therapeutics that treat a deficiency in thyroid activity by supplementing thyroid hormones.

Target Products:

  • Tirosint Capsule (Levothyroxine Sodium)
  
Immunology  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.

Buyer Products:

  • Elvitegravir/Formerly GS 9137 (HIV Integrase Inhibitor)
  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Emtriva (Emtricitabine)
  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  • Viread (Tenofovir Disoproxil Fumarate)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Infectious Diseases  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections by increasing permeability of the cell wall causing leakage of cellular contents.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Narrow Spectrum  
Nervous System  
Cryptococcal Meningitis  
Polyene Macrolide Antibiotics
Therapeutics that treat fungal infections of the lining of the brain and spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9190 (HCV Polymerase Inhibitor)
  • Viread (Tenofovir Disoproxil Fumarate)
  • LB84451 (Pan-Caspase Inhibitor)
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Visceral Leishmaniasis  
Polyene Macrolide Antibiotics
Therapeutics that treat infections characterized by Leishmania in macrophages by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • AmBisome (Amphotericin B)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Tamiflu (Oseltamivir)
  • Inhaled Therapeutics
  
Viral  
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months by blocking enzyme essential for viral DNA synthesis.

Buyer Products:

  • Hepsera (Adefovir Dipivoxil)
  • Viread (Tenofovir Disoproxil Fumarate)
  • Emtriva (Emtricitabine)
  
RNA Viruses  
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.

Buyer Products:

  • Elvitegravir/Formerly GS 9137 (HIV Integrase Inhibitor)
  
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine)
  • Emtriva (Emtricitabine)
  • Viread (Tenofovir Disoproxil Fumarate)
  
Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitors (NRTI/NNRTI)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate)
  
Musculoskeletal System  
Skeletal Disorders  
Joint Disorders  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Target Products:

  • Ketoprofen Transfersome Gel
  
Oncology  
Dermatology  
Kaposi`s Sarcoma  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of spindle cells by inhibiting a specific enzyme needed for transcription and replication of DNA.

Buyer Products:

  • DaunoXome (Liposomal Daunorubicin Injection)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9219 (Nucleotide Analog)
  
Ophthalmology  
Degenerative Disorders  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Vistide (Cidofovir)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.

Target Products:

  • Kadian (Morphine Sulphate Extended Release)
  
Narcotics  
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.

Target Products:

  • Embeda (Abuse Resistant Morphine Sulphate/Naltrexone)
  • Kadian (Morphine Sulphate Extended Release)
  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Target Products:

  • Flector Patch (Diclofenac Epolamine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Target Products:

  • ALO-02 (Oxycodone/Naltrexone)
  • ELADUR (TRANSDUR-Bupivacaine)
  • ALO-03
  • ALO-04
  
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Cystic Fibrosis (CF)  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Monobactams
Therapeutics that treat bacterial infections of the lung resulting as a complication of cystic fibrosis by inhibiting bacterial cell wall synthesis during active multiplication.

Buyer Products:

  • Inhaled Aztreonam Lysine
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • GS 9310/11 (Tobramycin And Fosfomycin)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • P-680 (Epithelial Sodium Channel (ENaC) Inhibitor)
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Target Products:

  • Alpharma Animal Health Division
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 115,304.202 10.92 7.15 2.36 2.37 4.27
Novartis AG (ADR) n/a 108,257.444 14.32 12.41 2.55 2.54 3.67
Abbott Laboratories n/a 81,473.569 17.92 15.86 2.83 2.76 27.79
Bristol Myers Squibb Co. n/a 45,599.400 11.65 13.73 2.20 2.20 6.62
BioDelivery Sciences International, Inc. n/a 47.142 n/a n/a 162.97 n/a n/a
Buyer
  Johnson & Johnson n/a 162,478.703 12.89 12.93 2.52 2.52 9.47
Roche Holding Ltd. (ADR) n/a 128,504.562 15.36 15.13 3.27 3.00 5.61
Target
  Pfizer Inc. n/a 115,304.202 10.92 7.15 2.36 2.37 4.27
Novartis AG (ADR) n/a 108,257.444 14.32 12.41 2.55 2.54 3.67
Abbott Laboratories n/a 81,473.569 17.92 15.86 2.83 2.76 27.79
Bristol Myers Squibb Co. n/a 45,599.400 11.65 13.73 2.20 2.20 6.62
Eli Lilly & Co. n/a 43,181.474 17.90 9.45 2.12 2.08 3.77
Teva Pharmaceutical Industries Ltd (ADR) n/a 33,970.080 17.95 14.84 3.14 3.07 7.59
Perrigo Company n/a 2,929.556 20.97 16.12 1.53 1.37 4.71
Endo Pharmaceuticals n/a 2,824.646 11.90 10.70 2.32 2.22 4.42
King Pharmaceuticals, Inc. n/a 2,479.481 9.60 8.48 1.42 1.63 1.27
XenoPort, Inc. n/a 555.251 n/a -8.50 9.72 14.35 5.84
Acura Pharmaceuticals, Inc. n/a 319.570 11.84 n/a 7.42 n/a 8.28
DURECT Corporation n/a 281.901 n/a -10.00 10.86 8.06 8.52
DepoMed, Inc. n/a 83.220 4.17 -3.21 2.65 2.61 1.92
Javelin Pharmaceuticals Inc. n/a 76.988 n/a -1.76 126.22 56.57 2.56
BioDelivery Sciences International, Inc. n/a 47.142 n/a n/a 162.97 n/a n/a
Penwest Pharmaceuticals n/a 41.801 n/a -1.40 9.75 5.09 2.74
Elite Pharmaceuticals, Inc. n/a 2.101 n/a n/a 1.05 n/a 0.26
Livzon Pharmaceutical Group Co., Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  DATATRAK International, Inc. 14.00% 3.851 n/a n/a 0.45 n/a n/a
Novartis AG (ADR) n/a 108,257.444 14.32 12.41 2.55 2.54 3.67
Abbott Laboratories n/a 81,473.569 17.92 15.86 2.83 2.76 27.79
Genelabs Technologies n/a 56.605 n/a -3.31 4.97 7.55 2.35
Monogram Biosciences, Inc. n/a 49.974 n/a -2.12 0.82 0.80 n/a
Achillion Pharmaceuticals, Inc. n/a 23.214 n/a -0.73 16.09 19.34 0.70
Parion Sciences, Inc. n/a n/a n/a n/a n/a n/a n/a
Emory University n/a n/a n/a n/a n/a n/a n/a
The University of Texas n/a n/a n/a n/a n/a n/a n/a
Target
  Bayer AG (ADR) n/a 42,099.954 5.82 10.59 0.92 1.04 n/a
Archer Daniels Midland Company n/a 18,185.796 7.54 8.16 0.23 0.24 1.40
Koninklijke DSM N.V. (ADR) n/a 3,957.680 4.32 3.99 0.29 n/a 0.65
Cambrex Corporation n/a 131.867 14.42 11.65 0.52 0.60 1.98
Kaken Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Actavis Group hf. n/a n/a n/a n/a n/a n/a n/a
Roquette America, Inc. n/a n/a n/a n/a n/a n/a n/a
IBSA Institut Biochimique SA n/a n/a n/a n/a n/a n/a n/a
Tris Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Cardinal Health, Inc. 20.00% 11,939.131 9.57 8.71 0.13 0.12 7.22
McKesson Corporation 15.00% 10,219.854 9.55 9.22 0.10 0.09 3.91
AmerisourceBergen Corp. 11.00% 5,375.489 21.45 10.84 0.08 0.08 n/a
Roche Holding Ltd. (ADR) 10.00% 128,504.562 15.36 15.13 3.27 3.00 5.61
GlaxoSmithKline plc (ADR) n/a 93,132.874 13.35 10.27 2.67 2.29 78.53
OSI Pharmaceuticals, Inc. n/a 2,193.437 18.31 17.36 6.00 5.65 13.77
XenoPort, Inc. n/a 555.251 n/a -8.50 9.72 14.35 5.84
Rexahn Pharmaceuticals, Inc. n/a 47.622 n/a n/a 653.85 n/a 11.20
Sumitomo Corporation n/a n/a n/a n/a n/a n/a n/a
Target
  Teva Pharmaceutical Industries Ltd (ADR) n/a 33,970.080 17.95 14.84 3.14 3.07 7.59
Alcon, Inc. n/a 25,696.909 12.85 14.04 4.10 4.07 6.98
Enzon Pharmaceuticals, Inc. n/a 260.282 n/a -32.33 1.32 1.51 n/a
Accentia Biopharmaceuticals, Inc n/a 6.040 n/a n/a 0.39 n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 128,504.562 15.36 15.13 3.27 3.00 5.61
Pfizer Inc. n/a 115,304.202 10.92 7.15 2.36 2.37 4.27
Novartis AG (ADR) n/a 108,257.444 14.32 12.41 2.55 2.54 3.67
GlaxoSmithKline plc (ADR) n/a 93,132.874 13.35 10.27 2.67 2.29 78.53
Abbott Laboratories n/a 81,473.569 17.92 15.86 2.83 2.76 27.79
Merck & Co., Inc. n/a 61,311.394 13.53 8.87 2.55 2.60 3.49
Bristol Myers Squibb Co. n/a 45,599.400 11.65 13.73 2.20 2.20 6.62
Cardinal Health, Inc. n/a 11,939.131 9.57 8.71 0.13 0.12 7.22
McKesson Corporation n/a 10,219.854 9.55 9.22 0.10 0.09 3.91
AmerisourceBergen Corp. n/a 5,375.489 21.45 10.84 0.08 0.08 n/a
OSI Pharmaceuticals, Inc. n/a 2,193.437 18.31 17.36 6.00 5.65 13.77
Target
  Bayer AG (ADR) n/a 42,099.954 5.82 10.59 0.92 1.04 n/a
Teva Pharmaceutical Industries Ltd (ADR) n/a 33,970.080 17.95 14.84 3.14 3.07 7.59
Alcon, Inc. n/a 25,696.909 12.85 14.04 4.10 4.07 6.98
Archer Daniels Midland Company n/a 18,185.796 7.54 8.16 0.23 0.24 1.40
Koninklijke DSM N.V. (ADR) n/a 3,957.680 4.32 3.99 0.29 n/a 0.65
DURECT Corporation n/a 281.901 n/a -10.00 10.86 8.06 8.52
Enzon Pharmaceuticals, Inc. n/a 260.282 n/a -32.33 1.32 1.51 n/a
Cambrex Corporation n/a 131.867 14.42 11.65 0.52 0.60 1.98
Accentia Biopharmaceuticals, Inc n/a 6.040 n/a n/a 0.39 n/a n/a
IBSA Institut Biochimique SA n/a n/a n/a n/a n/a n/a n/a
Tris Pharma, Inc. n/a n/a n/a n/a n/a n/a n/a
Actavis Group hf. n/a n/a n/a n/a n/a n/a n/a
Kaken Pharmaceutical Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Roquette America, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 5,002.3 650.3 5,652.6
Other Revenue 0.0 0.0 0.0
Total Revenue 5,002.3 650.3 5,652.6
Cost of Revenue 1,021.3 237.1 1,258.3
SG&A Expense 783.7 345.4 1,129.1
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 704.6 161.8 866.3
Interest Expense 0.0 0.0 0.0
Other Operating Expense 0.0 0.0 0.0
Unusual Expense (Income) 10.9 -0.2 10.7
Total Expenses 2,520.4 744.0 3,264.4
Operating Income 2,481.9 -93.7 2,388.1
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 66.1 6.7 72.8
Other, Net 0.0 -0.6 -0.6
Income Before Taxes 2,548.0 -87.6 2,460.3
Income Taxes 703.4 5.7 709.1
Income After Taxes 1,844.6 -93.3 1,751.3
Net Income - Excl. Xord. Items 1,844.6 -93.3 1,751.3
Discontinued Operations 0.0 207.5 207.5
Net Income - Incl. Xord. Items 1,844.6 114.1 1,958.8
Income Avail. to Common 1,844.6 114.1 1,958.8
Share Items
Basic Avg. Shares Outstanding 920.8 41.1 961.9
Basic EPS - Excl. Xord. Items 2.00 n/a 1.82
Basic EPS - Incl. Xord. Items 2.00 2.78 2.04
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 960.6 42.2 1,002.8
F.D. EPS - Excl. Xord. Items 1.92 n/a 1.75
F.D. EPS - Incl. Xord. Items 1.92 2.71 1.95
Balance Sheet
Assets
Cash and Equivalents 1,209.4 571.0 1,780.4
ST Investments 709.9 0.0 709.9
Accounts Receivable 1,047.2 98.6 1,145.8
Inventory 897.6 122.3 1,020.0
Prepayments and Advances 221.0 30.8 251.8
Other Current Assets 241.6 0.0 241.6
Current Assets 4,326.7 822.8 5,149.5
Accum D&A 0.0 0.0 0.0
PPE, Net 512.3 140.6 652.9
Goodwill & Intangibles 0.0 334.6 334.6
Long Term Investments 1,337.0 0.0 1,337.0
Other Assets 0.0 0.0 0.0
Other LT Assets 798.2 55.6 853.8
Total Assets 6,974.1 1,353.7 8,327.8
Liabilities
Accounts Payable 631.5 62.5 694.0
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 491.3 115.7 607.0
ST Debt 0.0 5.1 5.1
Curr Port of LTD & Cap Lease Oblg 6.1 0.0 6.1
Other (Current) Liabilities 130.2 0.0 130.2
Current Liab. 1,259.1 183.3 1,442.4
LT Debt 1,299.9 300.0 1,599.9
Total LT Debt 1,299.9 300.0 1,599.9
Minority Interest (BS) 127.6 0.0 127.6
Deferred Taxes 0.0 55.4 55.4
Other LT Liab. 121.6 30.4 152.0
Total Liabilities 2,808.2 569.1 3,377.4
Shareholders Equity
Common Stock 0.9 11.3 12.3
Additional Paid in Capital 3,616.8 1,150.7 4,767.5
Retained Earnings 531.0 1.6 532.6
Treasure Stock 0.0 -377.0 -377.0
Other Equity 17.2 -2.2 15.0
Total Equity 4,165.9 784.6 4,950.5
Total Liab. & Equity 6,974.1 1,353.7 8,327.8
Shares Outstanding 920.7 53.7 974.5
Cash Flow
Operating Cash Flow
CF Net Income 1,844.6 114.2 1,958.8
CF Depreciation 48.2 42.7 90.9
CF Amortization 36.9 0.0 36.9
CF Deferred Taxes 73.5 12.9 86.4
Other Non-Cash Items 180.7 -221.1 -40.3
Change in Working Capital -113.4 -4.0 -117.4
Total Cash From Operating Activities 2,070.6 -55.3 2,015.3
Investing Cash Flow (not calculated)
Capital Expenditures -92.7 -37.8 -130.4
Other Investing Cash Flows -454.7 384.5 -70.2
Total Cash From Investing Activities -547.4 346.7 -200.6
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock -1,015.2 -48.9 -1,064.2
Purchase and Retirement of Debt -3.8 3.0 -0.9
Other Financing Cash Flow 146.7 0.0 146.7
Total Cash From Financing Activities -872.3 -53.8 -926.2
Exchange Rate Effects -25.6 0.7 -24.9
Net Change in Cash 625.3 238.3 863.6
Cash Taxes Paid 565.2 5.4 570.6
Cash Interest Paid 7.5 6.6 14.0